The Zepto Capsulotomy system provides consistent, high-quality anterior lens capsulotomies during cataract surgery in a cost-effective, disposable format.
Based in Toronto, the Kensington Eye Institute is a leader in Canada for cataract, glaucoma and retina surgery. Home to some of the top eye surgeons in the country, Kensington pioneers the introduction and development of new ophthalmology technologies.
“The Zepto Capsulotomy System has received positive feedback with our customers in specific types of cataract surgeries,” said Ian Ball, CCO of Aequus.
“We’re proud to have the Zepto placed in one of the top clinics in Canada, where over 10,000 cataract surgeries are performed every year. This placement, along with the extension of the distribution agreement, provides further validation of Aequus’ ability to successfully commercialize assets within Canada.”
Aequus also announced it had extended its agreement with Mynosys Cellular Devices Inc to distribute Zepto in Canada to April 2022.
The company said the supplier relationship "does not imply any endorsement of the product nor imply a broader strategic relationship" between the parties.
Based in Vancouver, Aequus has several commercial products in ophthalmology and transplant in its pipeline and a development stage pipeline in neurology and psychiatry. Its most recent addition to the pipeline was a long-acting form of medical cannabis.
—(Updates with disclaimer)—
Contact Angela at [email protected]
Follow her on Twitter @AHarmantas